Cargando…

Impact of adherence to biological agents on health care resource utilization for patients over the age of 65 years with rheumatoid arthritis

OBJECTIVE: Poor adherence to therapy increases the patient and societal burden and complexity of chronic diseases such as rheumatoid arthritis (RA). In the past 15 years, biologic disease-modifying anti-rheumatic drugs (DMARDs) have revolutionized the treatment of RA. However, little data are availa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lathia, Urja, Ewara, Emmanuel M, Nantel, Francois
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505619/ https://www.ncbi.nlm.nih.gov/pubmed/28740368 http://dx.doi.org/10.2147/PPA.S137206

Ejemplares similares

Persistence to subcutaneous biological agents in Hungarian patients treated for inflammatory arthritis
por: Takacs, Peter, et al.
Publicado: (2019)

Estimating the Associated Burden of Illness and Healthcare Utilization of Newly Diagnosed Patients Aged ≥65 with Mantle Cell Lymphoma (MCL) in Ontario, Canada
por: Anglin, Peter, et al.
Publicado: (2023)

Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study
por: Ogale, Sarika, et al.
Publicado: (2011)

Damage progression in rheumatoid arthritis: the role of biologic agents
por: Favalli, Ennio Giulio
Publicado: (2012)

Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan
por: Mahlich, Jörg, et al.
Publicado: (2016)

Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database
por: Bhoi, Peter, et al.
Publicado: (2017)

The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era
por: Morgan, Catharine, et al.
Publicado: (2015)

Biologic agents for rheumatoid arthritis—negotiating the NICE technology appraisals
por: Kiely, Patrick D. W., et al.
Publicado: (2012)

Polymorphisms Involved in Response to Biological Agents Used in Rheumatoid Arthritis
por: Pallio, Giovanni, et al.
Publicado: (2020)

Biologic Agents in Rheumatoid Arthritis: An Update for Managed Care Professionals
por: Agarwal, Sandeep K.
Publicado: (2011)

High Adherence to System‐Level Performance Measures for Rheumatoid Arthritis in a National Early Arthritis Cohort Over Eight Years
por: Barber, Claire E. H., et al.
Publicado: (2018)

Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those ≥ 65 years of age
por: Tesser, John, et al.
Publicado: (2019)

Adherence to Methotrexate therapy in Rheumatoid Arthritis
por: Arshad, Nasim, et al.
Publicado: (2016)

Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
por: Mishra, Richa, et al.
Publicado: (2009)

Effects of Biologic Agents in Patients with Rheumatoid Arthritis and Amyloidosis Treated with Hemodialysis
por: Kuroda, Takeshi, et al.
Publicado: (2016)

Dopaminergic Agents in Rheumatoid Arthritis
por: Capellino, Silvia
Publicado: (2019)

Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry
por: Winthrop, Kevin L, et al.
Publicado: (2021)

Research on Liver Damage Caused by the Treatment of Rheumatoid Arthritis with Novel Biological Agents or Targeted Agents
por: Zhao, Xin, et al.
Publicado: (2023)

Thyroid Autoimmunity and Function after Treatment with Biological Antirheumatic Agents in Rheumatoid Arthritis
por: Bliddal, Sofie, et al.
Publicado: (2017)

Clinical outcomes and resource utilization analysis in patients with rheumatoid arthritis undergoing endoscopic retrograde cholangiopancreatography
por: Ahmed, Ahmed, et al.
Publicado: (2021)

Comparison of healthcare resource utilization and medical costs between patients with seropositive and seronegative rheumatoid arthritis
por: Kim, Hyoungyoung, et al.
Publicado: (2021)

Usage and Adherence of Seven Advanced Therapies with Differing Mechanisms of Action for Inflammatory Arthritis in Canada
por: Nantel, Francois, et al.
Publicado: (2022)

Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany
por: Neubauer, Sarah, et al.
Publicado: (2014)

Improving adherence to medical regimens for juvenile rheumatoid arthritis
por: Rapoff, Michael A, et al.
Publicado: (2007)

Self-Efficacy and Adherence Behaviors in Rheumatoid Arthritis Patients
por: Oshotse, Christiana, et al.
Publicado: (2018)

Adherence to Treatment in Patients with Rheumatoid Arthritis from Spain
por: Pombo-Suarez, Manuel, et al.
Publicado: (2021)

Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
por: Das, Priyam, et al.
Publicado: (2023)

Adherence and persistence of subcutaneous biologics delivered through homecare services to a cohort of patients with rheumatoid arthritis
por: Alvarez-Madrazo, Samantha, et al.
Publicado: (2017)

3′‐Sialyllactose as an inhibitor of p65 phosphorylation ameliorates the progression of experimental rheumatoid arthritis
por: Kang, Li‐Jung, et al.
Publicado: (2018)

Ceria-based nanotheranostic agent for rheumatoid arthritis
por: Kalashnikova, Irina, et al.
Publicado: (2020)

Biologic monotherapy in the treatment of rheumatoid arthritis
por: Detert, Jacqueline, et al.
Publicado: (2015)

Biologicals in rheumatoid arthritis: current and future
por: Avci, Ali Berkant, et al.
Publicado: (2015)

Treatment with Biologicals in Rheumatoid Arthritis: An Overview
por: Rein, Philipp, et al.
Publicado: (2017)

Psychosocial factors in adherence to pharmacological treatment and diabetes mellitus control in patients over 65
por: Lara-Morales, Alfredo, et al.
Publicado: (2022)

Utilizing Regulatory T Cells Against Rheumatoid Arthritis
por: Haque, Mohammad, et al.
Publicado: (2014)

Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2018)

Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis
por: Huynh, Tuan Khai, et al.
Publicado: (2014)

Treatment of rheumatoid arthritis with biological agents — as a typical and common immune-mediated inflammatory disease
por: TAKEUCHI, Tsutomu
Publicado: (2017)

Medicare expenditures for conventional and biologic disease modifying agents commonly used for treatment of rheumatoid arthritis
por: Dalal, Deepan S., et al.
Publicado: (2020)

Fusion proteins of biologic agents in the treatment of rheumatoid arthritis (RA): A network meta-analysis
por: Wu, Mingcai, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vf6uoi8ldiqmfleb5lhmce2pjv